Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-3BP-3940 is an investigational lutetium-177-labeled radiopharmaceutical developed by 3B Pharmaceuticals [1.2.5]. It consists of the cyclic peptide 3BP-3940, which is a structural variant of FAP-2286 designed with modifications to reduce renal uptake and retention, conjugated to a DOTA chelator and labeled with the beta-emitting radioisotope lutetium-177. The drug specifically targets fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts (CAFs) in the tumor microenvironment of various solid tumors. By binding to FAP, [177Lu]Lu-3BP-3940 delivers localized cytotoxic beta radiation directly to FAP-expressing tumors and their stroma [1.2.5]. It has been evaluated in preclinical models and used on a named-patient basis / investigator-initiated trials in patients with advanced metastatic solid tumors (such as pancreatic adenocarcinoma, breast cancer, lung cancer, and sarcomas) and high-grade muscle-invasive bladder cancer.
| Indication | Highest phase | Status |
|---|---|---|
| colorectal cancer (CRC) and precursor lesions | Preclinical | Active |
| lung cancer and precursor lesions | Preclinical | Active |
| metastatic breast cancer (mBC) | Preclinical | Active |
| muscle-invasive bladder cancer (MIBC) | Preclinical | Active |
| pancreatic ductal adenocarcinoma (PDAC) | Preclinical | Active |
| soft-tissue sarcomas | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: colorectal cancer (CRC) and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [177Lu]Lu-3BP-3940.
Work on [177Lu]Lu-3BP-3940? Claim this page to correct or add information. Claim this page